Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist

Recent advances on FXR-targeting therapeutics

(2022) Katrin Panzitt et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update

(2022) Nicholas Chew et al.   SEMINARS IN LIVER DISEASE

NAFLD 2020: The State of the Disease

(2020) Thomas G. Cotter et al.   GASTROENTEROLOGY

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

(2019) Maren H. Harms et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

(2019) Aliya F. Gulamhusein et al.   Nature Reviews Gastroenterology & Hepatology

Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis

(2017) Zhanyi Li et al.   PLoS One

Bile Acids as Hormones: The FXR-FGF15/19 Pathway

(2015) Steven A. Kliewer et al.   DIGESTIVE DISEASES

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET